Anchor Investment Management LLC Has $131,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. $REGN

Anchor Investment Management LLC trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 79.1% during the second quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 250 shares of the biopharmaceutical company’s stock after selling 946 shares during the quarter. Anchor Investment Management LLC’s holdings in Regeneron Pharmaceuticals were worth $131,000 as of its most recent filing with the SEC.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in REGN. State Street Corp increased its holdings in shares of Regeneron Pharmaceuticals by 0.9% during the second quarter. State Street Corp now owns 4,832,002 shares of the biopharmaceutical company’s stock worth $2,536,801,000 after buying an additional 42,343 shares in the last quarter. Dodge & Cox lifted its position in shares of Regeneron Pharmaceuticals by 64.6% in the 2nd quarter. Dodge & Cox now owns 3,826,283 shares of the biopharmaceutical company’s stock worth $2,008,799,000 after purchasing an additional 1,502,198 shares during the period. Franklin Resources Inc. lifted its holdings in Regeneron Pharmaceuticals by 1.6% in the second quarter. Franklin Resources Inc. now owns 2,313,496 shares of the biopharmaceutical company’s stock valued at $1,214,585,000 after buying an additional 36,821 shares during the period. Price T Rowe Associates Inc. MD boosted its position in shares of Regeneron Pharmaceuticals by 4.3% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,175,026 shares of the biopharmaceutical company’s stock valued at $1,379,467,000 after purchasing an additional 89,579 shares in the last quarter. Finally, Loomis Sayles & Co. L P boosted its holdings in shares of Regeneron Pharmaceuticals by 18.6% during the 2nd quarter. Loomis Sayles & Co. L P now owns 1,941,070 shares of the biopharmaceutical company’s stock worth $1,019,062,000 after buying an additional 305,089 shares in the last quarter. 83.31% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several research analysts have issued reports on REGN shares. Weiss Ratings reissued a “hold (c)” rating on shares of Regeneron Pharmaceuticals in a research note on Monday, December 8th. Raymond James Financial upgraded Regeneron Pharmaceuticals to a “moderate buy” rating in a research note on Tuesday, September 2nd. Hsbc Global Res upgraded shares of Regeneron Pharmaceuticals to a “strong-buy” rating in a research report on Monday, November 24th. BMO Capital Markets increased their price objective on Regeneron Pharmaceuticals from $725.00 to $850.00 and gave the company an “outperform” rating in a report on Thursday, December 4th. Finally, Guggenheim lifted their target price on shares of Regeneron Pharmaceuticals from $815.00 to $865.00 and gave the stock a “buy” rating in a research note on Wednesday, October 29th. Three analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, nine have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $779.45.

Regeneron Pharmaceuticals Price Performance

REGN opened at $752.62 on Tuesday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $790.98. The company has a current ratio of 4.06, a quick ratio of 3.33 and a debt-to-equity ratio of 0.09. The stock has a 50-day moving average price of $667.78 and a 200-day moving average price of $593.79. The stock has a market capitalization of $79.10 billion, a P/E ratio of 18.02, a PEG ratio of 2.12 and a beta of 0.37.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, October 28th. The biopharmaceutical company reported $11.83 earnings per share for the quarter, topping analysts’ consensus estimates of $9.73 by $2.10. The firm had revenue of $3.75 billion during the quarter, compared to analyst estimates of $3.57 billion. Regeneron Pharmaceuticals had a net margin of 32.13% and a return on equity of 13.76%. The business’s quarterly revenue was up .9% on a year-over-year basis. During the same period in the previous year, the business posted $12.46 EPS. Equities analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Friday, December 5th. Stockholders of record on Thursday, November 20th were given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.5%. The ex-dividend date was Thursday, November 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is currently 8.43%.

Insiders Place Their Bets

In other news, Director Christine A. Poon sold 6,500 shares of the stock in a transaction that occurred on Wednesday, October 29th. The stock was sold at an average price of $654.27, for a total value of $4,252,755.00. Following the completion of the transaction, the director owned 2,352 shares of the company’s stock, valued at approximately $1,538,843.04. This represents a 73.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Jason Pitofsky sold 431 shares of the stock in a transaction on Friday, November 7th. The stock was sold at an average price of $651.43, for a total value of $280,766.33. Following the completion of the transaction, the vice president owned 4,233 shares of the company’s stock, valued at approximately $2,757,503.19. This trade represents a 9.24% decrease in their position. The SEC filing for this sale provides additional information. 7.02% of the stock is currently owned by insiders.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.